Table 3.
The risk of all-grade myocardial infarction, heart failure, pericardial diseases, embolism, thrombosis and vasculis: subgroup analyses were carried out based on treatment lines.
| Treatment regimen | PD-1/PD-L1+chemotherapy VS chemotherapy | PD-1/PD-L1 VS chemotherapy | PD-1/PD-L1 VS placebo | |
|---|---|---|---|---|
| myocardial infraction | first line | OR=0.82, 95% CI [0.34, 1.96], p=0.65 | OR=1.22, 95% CI [0.30, 4.98], p=0.78 | OR=1.62, 95% CI [0.20, 13.22], p=0.65 |
| second or others | N/A | OR=0.31, 95% CI [0.03, 3.03], p=0.32 | OR=2.28, 95% CI [0.56, 9.25], p=0.25 | |
| heart failure | first line |
OR=1.08, 95% CI [0.52, 2.25], p=0.84 |
OR=0.48, 95% CI [0.16, 1.45], p=0.19 |
N/A |
| second or others | OR=4.05, 95% CI [0.45, 36.44], p=0.21 | OR=4.67, 95% CI [0.22, 97.56], p=0.32 | OR=2.62, 95% CI [0.52, 13.16], p=0.24 | |
| pericardial diseases | first line |
OR=1.90, 95% CI [0.45, 7.93], p=0.38 |
N/A | N/A |
| second or others | N/A | N/A | OR=3.30, 95% CI [0.57, 19.25], p=0.18 | |
| emobolism | first line |
OR=1.06, 95% CI [0.69, 1.64], p=0.79 |
OR=1.21, 95% CI [0.26, 5.65], p=0.81 |
OR=0.33, 95% CI [0.01, 8.24], p=0.50 |
| second or others | N/A | OR=2.90, 95% CI [0.12, 71.42], p=0.51 | OR=1.34, 95% CI [0.39, 4.65], p=0.64 | |
| thrombosis | first line | OR=1.41, 95% CI [0.70, 2.83], p=0.34 |
OR=0.64, 95% CI [0.20, 2.09], p=0.46 |
OR=0.54, 95% CI [0.09, 3.47], p=0.52 |
| second or others | N/A | OR=2.91, 95% CI [0.12, 71.76], p=0.51 | OR=0.58, 95% CI [0.12, 2.73], p=0.49 | |
| vasculitis | first line |
OR=1.51, 95% CI [0.86, 2.65], p=0.15 |
OR=0.82, 95% CI [0.17, 3.97], p=0.80 |
OR=1.35, 95% CI [0.09, 19.84], p=0.82 |
| second or others | N/A | OR=0.33, 95% CI [0.01, 8.19], p=0.50 | OR=1.38, 95% CI [0.27, 7.19], p=0.70 |
PD-1: Programmed cell death 1; PD-L1: Programmed cell death 1 ligand 1; OR: Odds Ratio; CI: Confidence Interval; N/A, not available.